Study Of Amatuximab For First-Line, Unresectable, Malignant Pleural Mesothelioma Patients Launched
News
Exton, Pennsylvania based Morphotek, Inc., the U.S. biopharmaceutical subsidiary of Tokyo-based global health care pharmaceutical company Eisai Co.,Ltd. — specializing in development of protein and antibody products through use of novel ... Read more